Treatment of demyelinating conditions

Details for Australian Patent Application No. 2004226334 (hide)

Owner NeuroMolecular, Inc.

Inventors Went, Greg; Lipton, Stuart; Meyerson, Lawrence

Agent Cullen & Co

Pub. Number AU-A-2004226334

PCT Pub. Number WO2004/087073

Priority 60/458,050 27.03.03 US

Filing date 29 March 2004

Wipo publication date 14 October 2004

International Classifications

A61K 031/13 - Amines, e.g. amantadine

Event Publications

10 November 2005 PCT application entered the National Phase

  PCT publication WO2004/087073 Priority application(s): WO2004/087073

22 October 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004226335-Therapeutic agent delivery device with controlled therapeutic agent release rates

2004226328-Implantable medical device and method for in situ selective modulation of agent delivery